We noted a significant increase of interleukin-8 (IL-8), LBP and CRP mirroring the pattern of mucosal barrier injury as measured by gut integrity (lactulose/rhamnose ratio), daily mucositis score (DMS) and serum citrulline concentrations of 32 haematopoietic stem cell transplant (HSCT) recipients following intensive myeloablative therapy. Concentrations of IL-8, LBP and CRP were already significantly elevated before the onset of fever or bacteraemia due to oral viridans streptococci (OVS) in the first week after transplant during profound neutropenia. These markers reached their peak when citrulline concentrations reached their nadir, the highest scores of DMS were attained and when there was significantly decreased gut integrity. This suggests that the degree of mucosal barrier injury rather than bacteraemia due to OVS determines the intensity of the inflammatory response. 1 It begins immediately after starting anticancer therapy with the activation of the nuclear transcription factor NF-kB resulting in the production and release of proinflammatory cytokines by various cells including lymphocytes, macrophages, endothelial cells and gut epithelial cells.
Mucosal barrier injury (MBI) of the digestive tract induced by intensive cytotoxic therapy is a complex pathobiological process. 1 It begins immediately after starting anticancer therapy with the activation of the nuclear transcription factor NF-kB resulting in the production and release of proinflammatory cytokines by various cells including lymphocytes, macrophages, endothelial cells and gut epithelial cells. 2, 3 Gut epithelial cells produce not only proinflammatory cytokines like TNF-a, interleukin (IL)-1a and IL-6, but also the chemokines, monocyte chemoattractant protein-1 (MCP-1) and IL-8, antimicrobial peptides (defensins, cathelicidins, lactoferrin) and the acute phase protein, LPS-binding protein (LBP). [3] [4] [5] The release of proinflammatory cytokines and the blocking of clonogenic epithelial stem cell renewal results in apoptosis and necrosis, which manifests itself as epithelial atrophy and ulcerative lesions. 6 The latter are a potential portal of entry for oral viridans (alpha-haemolytic) streptococci (OVS), which are universal commensals of the oral cavity placing haematopoietic stem cell transplant (HSCT) recipients at risk of developing bacteraemia due to these bacteria. 7 Our standard myeloablative regimen of idarubicin, cyclophosphamide and TBI to prepare patients for a T-cell depleted HSCT 8 is known to induce prolonged and severe MBI of the oral cavity and digestive tract. 9 This is invariably accompanied by fever and bacteraemia due to frequent occurrence of viridans streptococci 10 as well as the continued release of C-reactive protein (CRP) (unpublished observation). We prospectively routinely determined CRP concentrations throughout admission of 32 HSCT recipients participating in a prospective randomised placebo-controlled study of glutamine-dipeptide-enriched parenteral nutrition and collected serum and plasma samples for measuring IL-8 and LBP later. We were particularly interested in investigating production of IL-8 and LBP together with CRP to determine the proinflammatory response of the gut during the process of MBI as defined by oral mucositis, sugar permeability tests (SPT) and serum citrulline concentrations.
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Patients and methods
Patients
A total of 32 patients (12 F; 20 M) with a mean age of 48 years (range 25-65) had given their informed consent to participate in the prospective study of glutamine-enriched total parenteral nutrition which required the collection of blood and urine, respectively, for amino-acid analysis and sugar permeability testing, and was approved by the Ethics Committee. All had received an HLA-matched T-celldepleted sibling HSCT to treat a haematological malignancy (AML (9), ALL (7), NHL (7), MDS (3), CML (2), MPD (2), CLL (1), MF(1)). On admission, a triple lumen intravascular catheter (IVC) was inserted into the subclavian vein. The myeloablative regimen started on HSCT day À12. Idarubicin was given at a dose of 42 mg/m 2 by continuous infusion over 48 h, followed by 120 mg/kg cyclophosphamide (60 mg/kg/day) on HSCT days À6 and À5 and TBI (4.5 Gy/day) on HSCT days À2 and À1. All recipients were given parenteral nutrition on HSCT day À6 supplemented with either glutamine-dipeptide or placebo. Cyclosporin 3 mg/kg/day was given by continuous infusion as prophylaxis against GVHD for the first 2 weeks after transplant followed by 2 mg/kg/day until oral intake was possible. Haematopoietic growth factors were not used. Antiinfective prophylaxis was administered orally and consisted of ciprofloxacin, acyclovir or valaciclovir and cotrimoxazole (sulphamethoxazole-trimethoprim). Fluconazole was only given orally to patients colonised with C. albicans. No other systemic antifungal agents were given for prophylaxis. Full blood counts with absolute neutrophil count (ANC) together with renal and liver function tests were performed daily. Oral gargle samples and faeces was obtained twice weekly for culture to detect the presence of Gram-negative bacilli and yeasts. Cefepime or ceftazidime was administered empirically at the onset of fever (438.51C once or 4381C sustained for 46 h during neutropenia (ANCo0.5 Â 10 9 /l).
Blood cultures
From each lumen of the IVC, 10 ml of blood was obtained, for aerobic culture at approximately 0900 hours every Monday and Thursday on HSCT days À12, À6, À2, þ 1,
At the onset of fever, two additional blood cultures were obtained from each lumen of the IVC together with two 20 ml samples drawn through two separate peripheral veins within 30 min of each other. Bacteraemia due to viridans streptococci was considered present when the organism was recovered from a single blood culture from any source. Isolates were identified as OVS on the basis of cultural appearance, Gram stain and morphology, resistance to optochin and the identification of Streptococcus mitis, Streptococcus oralis or Streptococcus sanguis using the API 20S STREP kit (bioMe´rieux sa, Marcy l'Etoile, France). 
Mucosal barrier injury
Citrulline. The protocol prescribed serum to be obtained on HSCT days À12, À6, 0, þ 7, þ 14 and þ 21 for later amino-acid analysis. In practice, this was not always performed. Serum taken was stored at À801C. Citrulline concentrations (mM) were measured by a standard procedure for determining amino acids using automated ion exchange column chromatography after closing of the study. 12 Oral mucositis assessment. Patients were monitored daily by trained nurses for the presence of oral mucositis evidenced by lesions, erythema, oedema, pain, bleeding, dryness and the production of viscous mucous with each item being allocated a score of 0 or normal to 3 or severe. The separate values were summed to yield a daily oral mucositis score (DMS) with 3 grades: DMS grade I (1-7 points) mild mucositis, grade II (8-14 points) moderate mucositis and grade III (414 points) severe mucositis. The DMS grade is comparable with the WHO scale. 13 
Sugar permeability test
The SPT was performed as previously described. 9 Briefly, after an overnight fast, the subjects emptied their bladders and then drank an isotonic solution containing 5 g lactulose, 1 g L-rhamnose, 0.2 g 3-O-methylglucose (OMG), 0.5 g D-xylose in 100 ml demineralised water. Urine was then collected for 5 h after which the total volume passed was recorded, and aliquots of approximately 5 ml were stored at À801C until analysis was performed. The first SPT (baseline day) was performed before starting conditioning therapy and was repeated every Wednesday after baseline on HSCT days À12, À6, 0, þ 7, þ 14 and þ 21. Urinary excretion was determined using gas chromatography and urinary recovery of each sugar was expressed as a percentage of the intake. Lactulose is a disaccharide that is absorbed by paracellular transport, that is, via open tight junctions and the villous tip extrusion zone. Hence, any increase in urinary excretion represents loss of integrity. The other sugars are monosaccharides with L-rhamnose being used to monitor passive transcellular diffusion, Dxylose to detect carrier-mediated transcellular transport and 3-OMG to measure ATP-dependent transcellular transport. A decrease in urinary excretion of any of these sugars indicates reduced uptake because of a smaller surface area of the gut implying a loss of epithelial cell function or number. The lactulose/rhamnose ratio (L/R) was used as an index of intestinal permeability or integrity with an L/R ratio of 0.02 or less being considered normal.
Statistical analysis
SPSS for windows software (Release 12.1) was used for statistical analysis. All results are expressed as the mean with 95% CI. One-way analysis of variance (ANOVA) was used to analyse changes in the concentrations of CRP, IL-8, LBP and citrulline, sugar test recoveries, L/R ratio, ANC and maximum daily temperature. CRP was measured daily but only those samples taken on or within a day of SPT being performed were used. Student's t-test was performed to investigate differences with respect to baseline values. The correlation between citrulline concentration, urinary recovery of sugars and the L/R ratio was estimated using Pearson's procedure. A P-value o0.05 was considered statistically significant for all analyses.
Results
Mucosal barrier injury
Oral mucositis (DMS) was present for the first 3 weeks after transplant and showed a clear peak 1 week after transplant ( Figure 1a ) coinciding with the nadir of citrulline concentrations (Figure 1b) . Citrulline concentrations and the recovery of D-xylose, L-rhamnose and 3-OMG, but not lactulose, were significantly decreased on the day of transplant as compared to the baseline values, that is, 12 days after starting myeloablative therapy (Po0.0001). (Table 1 ) The L/R ratio was significantly increased on the day of transplant (Po0.0001) with respect to the baseline indicating loss of integrity (Figure 1c) .
Inflammatory response
CRP, IL-8 and LBP concentrations shown, respectively, in Figure 2a , b and c and were significantly increased by the day of transplant and their peak occurred 1 week later (Table 2 ) when patients were profoundly neutropenic. The maximum temperature followed the same pattern with the highest mean value (38.21C) occurring 1 week after transplant. The administration of glutamine-dipeptide had no influence on IL-8 or LBP concentrations (data not shown). However, CRP concentrations were significantly lower on HSCT day þ 21 for those patients receiving glutamine (34 vs 74, P ¼ 0.003). CRP concentrations were significantly correlated, respectively, with those of LBP, r ¼ 0.85, IL-8, r ¼ 0.62, L/R ratio, r ¼ 0.46 and citrulline, r ¼ À0.43.
OVS bacteraemia
All except one patient were treated empirically for fever during neutropenia with a cephalosporin. Eleven patients had bacteraemia due to OVS occurring between HSCT days þ 1 and þ 8. Mean concentrations of CRP, IL-8 and LBP measured on HSCT day ¼ 0 were already significantly increased before the onset of OVS bacteraemia and MBI was manifest as measured by low citrulline concentrations, perturbed gut integrity and increased DMS. There were no significantly different results on HSCT day ¼ 0 or at baseline for patients who developed OVS bacteraemia (data not shown). Table 1 Mean ( The daily mucositis score (DMS) of the study population was already significantly higher on the day of transplant and reached a peak 1 week later, whereas for citrulline concentrations the converse was true. Thereafter, the DMS declined steadily while citrulline concentrations rose slightly but remained low. The L/R ratio was significantly increased by day of transplant and remained more or less at that level 3 weeks later at the time of discharge. The lines represent the mean values and the asterisk indicates a significant difference from baseline.
Gram-negative bacilli
Acinetobacter baumanii was recovered from a single aerobic blood culture from one patient on day þ 1 after transplant, but no other Gram-negative bacilli were recovered from blood cultures or surveillance specimens of any other patient during the study period.
Discussion
MBI measured by DMS, citrulline and SPT followed a clear pattern beginning 13 days after starting myeloablative therapy and reached a peak 1 week later, as did the levels of CRP, IL-8 and LBP. These markers of inflammation therefore appear to reflect the burden of gut mucosal damage. A similar pattern of elevated markers of inflammation has been noted before in the first 2 weeks after transplant. CRP, IL-8 and LBP concentrations reached a peak 20 days after therapy, that is, 1 week after transplant. This might be a result of endothelial cells or surviving immune effector cells responding to invading bacteria. 14 However, only 11 patients developed OVS bacteraemia and although CRP, IL-8 and LBP concentrations were already increased before the onset of OVS bacteraemia they were not different from those of patients who did not develop bacteraemia. Markedly elevated LBP and CRP levels were also found by Levy et al 15 1 week after transplant among paediatric SCT recipients with endotoxaemia, not bacteraemia, being found in four,that is, a third of the 14 patients on the day of transplant. The authors postulated that LBP and CRP were predominantly produced by the liver in response to LPS. We did not attempt to determine endotoxin in our study but think that its role is likely to be minor and involve a similar proportion of patients as was found by Levy et al. 15 Furthermore, no enteric or any other Gram-negative bacteria was recovered from aerobic cultures of oral and faecal specimens obtained twice weekly throughout the study, and there was only a single episode of bacteraemia due to A. baumannii which is not a typical commensal of the alimentary tract. It is possible that the presence of ciprofloxacin in blood cultures may have impaired the recovery of Gram-negative bacteria and we made no attempt to recover anaerobic gut bacteria that possess LPS, for example, Bacteroides from our surveillance cultures. Nevertheless, our results suggest that MBI rather than bacteria initiate the systemic inflammatory response. Indeed, the release of proinflammatory cytokines has been shown in rats given 5 FU to be associated with evolving MBI and to precede microbial translocation. 16 Moreover, translocation of microorganisms from the lumen of the gut is thought to be promoted when the integrity of the mucosal barrier is impaired by anticancer therapy. 17 Similar bacteria as those recovered from blood have also been shown to be already present in the gut lumen at the start of chemotherapy, well before bacteraemia occurs, signifying that their presence is necessary but not sufficient to lead to bacteraemia but that disturbances of the mucosal barrier are a prerequisite. 18 It therefore seems that MBI directly triggers a systemic inflammatory response that precedes the onset of bacteraemia and that bacteria play little, if any, role. Consequently, preventing or restoring damage to the mucosal barrier may provide a more effective means of preventing bacteraemia after transplant than antimicrobial prophylaxis.
